Published in Br J Haematol on July 06, 2012
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood (2013) 1.44
Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies. Front Immunol (2014) 0.98
Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions. Front Immunol (2015) 0.86
Changes in follicular helper T cells in idiopathic thrombocytopenic purpura patients. Int J Biol Sci (2015) 0.79
Human FcR polymorphism and disease. Curr Top Microbiol Immunol (2014) 0.79
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet (2010) 4.20
Transfusion-related acute lung injury: definition and review. Crit Care Med (2005) 3.98
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (2008) 3.74
B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol (2011) 3.66
Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer (2010) 3.55
Vancomycin-induced immune thrombocytopenia. N Engl J Med (2007) 3.35
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr (2005) 2.97
The ITP syndrome: pathogenic and clinical diversity. Blood (2009) 2.83
The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol (2010) 2.55
KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med (2004) 2.39
HIV-associated lymphomas and gamma-herpesviruses. Blood (2008) 2.27
Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood (2010) 2.21
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood (2008) 2.13
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
How I treat idiopathic thrombocytopenic purpura (ITP). Blood (2005) 2.05
Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood (2008) 2.03
Bone loss caused by iron overload in a murine model: importance of oxidative stress. Blood (2010) 1.98
Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood (2009) 1.96
Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood (2003) 1.93
Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc Natl Acad Sci U S A (2009) 1.91
Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood (2011) 1.89
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood (2012) 1.88
Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol (2009) 1.84
Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood (2003) 1.81
Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol (2009) 1.78
Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol (2003) 1.70
KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol (2004) 1.69
Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood (2013) 1.68
Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev (2002) 1.67
Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood (2008) 1.63
Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica (2007) 1.62
CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J Exp Med (2007) 1.61
NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood (2005) 1.56
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood (2008) 1.52
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol (2010) 1.51
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood (2012) 1.50
Percutaneous laser ablation in the treatment of hepatocellular carcinoma with small tumors: analysis of factors affecting the achievement of tumor necrosis. J Vasc Interv Radiol (2005) 1.50
Human herpesvirus-8-associated lymphoma of the bowel in human immunodeficiency virus-positive patients without history of primary effusion lymphoma. Hum Pathol (2002) 1.49
Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol (2008) 1.45
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol (2004) 1.43
Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol (2006) 1.43
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol (2009) 1.41
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood (2012) 1.40
Rituximab in B-cell disorders other than non-Hodgkin's lymphoma. Anticancer Drugs (2002) 1.40
Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program (2004) 1.38
Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood (2012) 1.38
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol (2005) 1.38
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood (2005) 1.37
Pathobiology of secondary immune thrombocytopenia. Semin Hematol (2009) 1.35
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood (2006) 1.35
Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol (2013) 1.33
ANKRD26-related thrombocytopenia and myeloid malignancies. Blood (2013) 1.32
Clinicopathologic features of agranulocytosis in the setting of levamisole-tainted cocaine. Am J Clin Pathol (2010) 1.31
How I treat thrombocytopenia in pregnancy. Blood (2012) 1.31
Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2007) 1.30
Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol (2005) 1.30
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol (2013) 1.30
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood (2012) 1.28
The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. J Virol (2003) 1.26
New platelet glycoprotein polymorphisms causing maternal immunization and neonatal alloimmune thrombocytopenia. Transfusion (2011) 1.21
Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood (2002) 1.21
NF-kappaB signaling modulation by EBV and KSHV. Trends Microbiol (2010) 1.20
Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol (2003) 1.16
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol (2008) 1.14
Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J Exp Med (2013) 1.14
Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood (2002) 1.12
The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol (2007) 1.11
Neonatal alloimmune thrombocytopenia associated with maternal-fetal incompatibility for blood group B. Transfusion (2007) 1.10
Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol (2004) 1.10
Alloimmune thrombocytopenia: state of the art 2006. Am J Obstet Gynecol (2006) 1.10
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood (2007) 1.09
EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression. Blood (2008) 1.09
Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer (2008) 1.09
The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling. EMBO Rep (2006) 1.08
Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.07
Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice. J Clin Invest (2011) 1.06
Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood (2007) 1.05
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol (2011) 1.04
Analysis of the human herpesvirus 8 (HHV-8) genome and HHV-8 vIL-6 expression in archival cases of castleman disease at low risk for HIV infection. Am J Clin Pathol (2002) 1.03
Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol (2007) 1.03
Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol (2006) 1.02
Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr (2011) 1.02
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol (2009) 1.01
Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Max a) is an important cause of neonatal alloimmune thrombocytopenia. Transfusion (2005) 1.01